Invivyd announces selection of RSV antibody candidate VBY329

Invivyd (IVVD) identified and nominated for preclinical development a monoclonal antibody candidate for the prevention of Respiratory Syncytial Virus among neonates, infants, and children. Invivyd’s investigational antibody, VBY329, was generated by Invivyd’s proprietary antibody discovery technology, targeted at high value infectious diseases. RSV is a common respiratory illness and is the leading cause of hospitalization for infants in the United States. VBY329 follows from a discovery strategy that required it to demonstrate differential binding activity against pre-fusion stabilized F proteins from RSV-A2 and RSV-B313726, as well as proteins encoding resistance determinants to nirsevimab, and to demonstrate improved neutralization potency within a pseudovirus panel representing this collection of variants. Invivyd anticipates that success along these lines demonstrates biophysical properties that may predict best-in-class clinical performance compared to standard of care. Invivyd expects to present in vitro VBY329 data at a future medical congress. Invivyd is moving VBY329 into IND-enabling processes with a goal of IND readiness in the second half of 2026. Invivyd, via its proprietary technology platform, continues to investigate additional monoclonal antibodies for protection and treatment of important infectious diseases, such as measles, among vulnerable populations.